Alumis Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALMS Nasdaq 2836 www.alumis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alumis Inc.

Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population - Sep 8th, 2026 7:30 pm
Alumis to Participate in Upcoming September Investor Conferences - Sep 4th, 2026 6:00 am
Is Alumis (ALMS) Overvalued After Its 121% One Year Return? - Sep 3rd, 2026 8:10 am
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy - Sep 3rd, 2026 6:15 am
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair? - Sep 3rd, 2026 5:06 am
Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints - Sep 3rd, 2026 2:17 am
Sector Update: Healthcare Stocks Advance Late Afternoon - Sep 2nd, 2026 1:43 pm
Top Midday Gainers - Sep 2nd, 2026 11:50 am
Sector Update: Healthcare Stocks Advance Wednesday Afternoon - Sep 2nd, 2026 11:38 am
Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says - Sep 2nd, 2026 9:40 am
ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff? - Sep 1st, 2026 5:55 pm
Tesla, Apple, Nvidia, Medtronic, Alumis, Robinhood, Fervo, and More Stocks That Explain Today’s Market - Sep 1st, 2026 2:24 pm
A Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It - Sep 1st, 2026 11:23 am
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise - Sep 1st, 2026 9:02 am
Alumis Phase 2b lupus trial misses primary and secondary endpoints - Sep 1st, 2026 8:03 am
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) - Sep 1st, 2026 5:30 am
Alumis’ TYK2 drug fails in key lupus study - Sep 1st, 2026 5:28 am
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements - Aug 13th, 2026 2:01 pm